DIABETES & METABOLISM, published by MASSON EDITEUR in France, is a leading academic journal dedicated to the fields of endocrinology, diabetes, and metabolism. With an impressive Impact Factor reflecting its esteemed reputation, the journal has been ranked in the Q1 category across multiple disciplines including Endocrinology, Internal Medicine, and more, showcasing its significance and influence in the scientific community. Since its inception in 1996 and continuing its contributions through 2024, DIABETES & METABOLISM systematically disseminates high-quality research findings, reviews, and clinical studies aimed at furthering knowledge and encouraging innovation in metabolic diseases. Although not an open-access journal, it ensures that valuable research is accessible to a broad audience through institutional subscriptions and affiliations. As a key resource for researchers, clinicians, and students alike, this journal stands at the forefront of advancing understanding and treatment options in diabetes and related metabolic disorders, making it an essential addition to any academic library.

Diabetes & Metabolism Journal, published by the Korean Diabetes Association, is a leading open-access journal dedicated to advancing the field of endocrinology, with a specific focus on diabetes and metabolism. Since its establishment in 1991, the journal has provided a robust platform for disseminating high-quality research, contributing significantly to our understanding of diabetes pathophysiology, treatment, and prevention strategies. The journal boasts an impressive impact factor, ranking in the top quartile (Q1) of its category and occupying the 28th position out of 244 in Scopus rankings, which places it in the 88th percentile among its peers. With its commitment to open access, researchers, professionals, and students globally can explore the latest findings and innovative solutions in diabetes research. The journal continues to serve as an essential resource for those dedicated to improving patient outcomes and advancing scientific knowledge in the metabolic disorders domain.

The International Journal of Diabetes in Developing Countries, published by SPRINGER INDIA, stands as a pivotal resource in the field of diabetes research, particularly focusing on the challenges and advancements in diabetes management within developing nations. With an ISSN of 0973-3930 and an E-ISSN of 1998-3832, this journal has been fostering knowledge exchange since its inception in 2001, converging its focus over multiple years to maintain relevance through 2024. As a peer-reviewed journal, it holds a significant position within the Q4 category of Endocrinology, Diabetes and Metabolism and Q3 in Internal Medicine, showcasing its commitment to addressing critical issues regarding diabetes care in diverse populations. The journal is crucial for researchers, healthcare professionals, and students seeking to further their understanding of diabetes in resource-limited settings. Although it operates without an open access model, the journal ensures rigorous peer review, maintaining high academic standards that benefit the growing field of diabetes research. With its address located in the heart of New Delhi, India, this publication serves as a vital repository for valuable insights and innovative strategies aimed at combating diabetes in developing countries.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

Primary Care Diabetes is a leading journal published by ELSEVIER SCI LTD, focusing on the intersection of diabetes care, endocrinology, and family medicine. Since its inception in 2007, the journal has made significant contributions to the field, achieving notable rankings in various categories, such as Q2 in Endocrinology, Diabetes and Metabolism, Q1 in Family Practice, and Q2 in Internal Medicine, as well as Nutrition and Dietetics for 2023. With an ISSN of 1751-9918 and an E-ISSN of 1878-0210, it serves as an essential resource for researchers, healthcare professionals, and students dedicated to advancing knowledge and practice in primary diabetes care. The journal's strong Scopus rankings reflect its commitment to publish high-quality research, fostering clinical practice improvements and enhanced patient outcomes. Although not open access, its articles are pivotal for anyone looking to stay ahead in the dynamic and vital domain of diabetes management.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.

Diabetes Technology & Therapeutics is a leading journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of diabetes management through innovative technologies and therapeutic strategies. With an impressive impact factor and recognized as a Q1 journal in Endocrinology, Diabetes and Metabolism, as well as Medical Laboratory Technology, it occupies a pivotal position in the academic landscape. This esteemed publication features a comprehensive range of articles that cover cutting-edge research, clinical applications, and developments in diabetes care from 1999 to 2024, making it a critical resource for researchers, health professionals, and students alike. The journal is committed to fostering dialogue between disciplines, especially given its strong rankings in various scientific categories including the 98th percentile in Medical Laboratory Technology. By opting for subscription-based access, readers gain insight into the latest innovations that are shaping diabetes technology and treatment paradigms, thereby enhancing patient outcomes and advancing the scientific community's understanding of this complex disease.

The British Journal of Diabetes, published by the Association of British Clinical Diabetologists, is a premier journal dedicated to advancing the understanding, prevention, and management of diabetes. With an ISSN of 2397-6233, this journal aims to disseminate high-quality research findings, clinical studies, and reviews that address the complexities of diabetes care and research. While currently not available as an open access option, the journal is committed to enhancing the visibility of cutting-edge diabetes research for healthcare professionals and academics. Located in the heart of England, this journal plays a crucial role in bridging the gap between clinical practice and research innovation, making it an essential resource for practitioners, researchers, and students alike. The British Journal of Diabetes is determined to contribute significantly to the global dialogue on diabetes, as it covers a wide spectrum of topics from epidemiology and public health to novel therapeutic strategies and patient management approaches.

DIABETOLOGIA is a leading journal in the field of endocrinology and diabetes research, published by Springer since its inception in 1965. With an impactful presence in both Internal Medicine and Endocrinology, Diabetes and Metabolism, it is recognized in the Q1 quartile rankings for 2023, underscoring its significance and contribution to these disciplines. The journal holds impressive Scopus rankings, placing it in the top 5% of journals in its categories, making it an essential resource for researchers, healthcare professionals, and students dedicated to advancing knowledge and practices in diabetes care and management. DIABETOLOGIA publishes a range of peer-reviewed articles, original research, and reviews that address the latest scientific developments, clinical practices, and therapeutic innovations, contributing to the global discourse on diabetes and its related health implications. Although it does not offer Open Access options, its rigorous selection process guarantees the quality and relevance of the content, solidifying its position as a reliable reference for contemporary research. For those looking to stay at the forefront of diabetes science, DIABETOLOGIA is a vital communique in the ever-evolving landscape of medical research.

Diabetes Mellitus, published by the Endocrinology Research Centre in the Russian Federation, is an esteemed open-access journal dedicated to the field of endocrinology, diabetes, and metabolism. Since its inception in 1998, this journal has been a pivotal platform for disseminating cutting-edge research and comprehensive reviews that address the multifaceted challenges posed by diabetes. With its current quartile ranking of Q4 in Endocrinology and the associated fields, as well as commendable involvement in the broader scope of Internal Medicine, Diabetes Mellitus plays a crucial role in enhancing clinical practices and informing innovative therapeutic strategies. The journal caters to a diverse audience of researchers, healthcare professionals, and students, particularly those seeking to expand their knowledge and improve patient outcomes in diabetes care. With a commitment to fostering scientific conversation and collaboration, Diabetes Mellitus is an invaluable resource for anyone engaged in the fight against diabetes and its complications.